Tvardi Therapeutics (TVRD) Competitors $22.46 +1.01 (+4.71%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock TVRD vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYREShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors Oculis Chimerix Avid Bioservices uniQure CorMedix Cronos Group GH Research Syndax Pharmaceuticals Immunome Gyre Therapeutics Tvardi Therapeutics (NASDAQ:TVRD) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Do analysts rate TVRD or OCS? Tvardi Therapeutics currently has a consensus price target of $71.50, suggesting a potential upside of 218.34%. Oculis has a consensus price target of $35.33, suggesting a potential upside of 86.41%. Given Tvardi Therapeutics' higher possible upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, TVRD or OCS? Tvardi Therapeutics has higher revenue and earnings than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTvardi Therapeutics$7.14M29.44-$70.87MN/AN/AOculis$780K1,060.99-$97.43M-$2.64-7.18 Is TVRD or OCS more profitable? Tvardi Therapeutics has a net margin of -595.39% compared to Oculis' net margin of -13,788.70%. Oculis' return on equity of -92.95% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics-595.39% -710.04% -79.00% Oculis -13,788.70%-92.95%-70.03% Do insiders and institutionals believe in TVRD or OCS? 44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to TVRD or OCS? In the previous week, Oculis had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 1 mentions for Oculis and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Oculis'average media sentiment score. Company Overall Sentiment Tvardi Therapeutics Neutral Oculis Neutral Which has more volatility & risk, TVRD or OCS? Tvardi Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. SummaryTvardi Therapeutics and Oculis tied by winning 6 of the 12 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.23M$2.92B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.5627.6520.23Price / Sales29.44283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book-7.447.538.035.65Net Income-$70.87M-$55.14M$3.18B$249.15M7 Day Performance-3.73%4.22%2.88%2.91%1 Month Performance-21.19%0.91%1.67%4.11%1 Year PerformanceN/A5.40%34.39%20.98% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi TherapeuticsN/A$22.46+4.7%$71.50+218.3%N/A$210.23M$7.14M0.0080OCSOculis1.7287 of 5 stars$18.96-1.1%$35.33+86.4%+62.6%$829.59M$780K-7.182News CoverageCMRXChimerix0.6197 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.1206 of 5 stars$14.49+1.4%$37.82+161.1%+277.2%$789.86M$27.12M-3.30500CRMDCorMedix2.5782 of 5 stars$11.64+0.4%$17.14+47.3%+182.5%$788.12M$43.47M52.9130CRONCronos Group2.0073 of 5 stars$2.04+2.0%N/A-8.5%$786.79M$117.61M15.69450News CoverageGHRSGH Research1.5715 of 5 stars$14.91-0.8%$32.00+114.6%+26.9%$776MN/A-18.8710News CoverageAnalyst UpgradeSNDXSyndax Pharmaceuticals3.1224 of 5 stars$9.28+3.1%$35.80+285.9%-55.7%$774.43M$23.68M-2.40110IMNMImmunome2.4317 of 5 stars$8.71+0.9%$23.33+167.9%-27.6%$769.19M$9.04M-2.7440GYREGyre Therapeutics0.0779 of 5 stars$8.14+4.4%N/A-34.5%$762.25M$105.76M407.2040 Related Companies and Tools Related Companies Oculis Alternatives Chimerix Alternatives Avid Bioservices Alternatives uniQure Alternatives CorMedix Alternatives Cronos Group Alternatives GH Research Alternatives Syndax Pharmaceuticals Alternatives Immunome Alternatives Gyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
